The biotechnology company is a pioneer in gene editing.

Updates from The Motley Fool

Latest updates on Editas Medicine from
3 Stocks I'd Never Touch

Northern Dynasty Minerals, Resolute Energy, and Editas Medicine are scorching-hot stocks, but I w...

The Unsung Heroes of CAR-T

Investors are well aware of the big names in CAR-T therapies, but these companies are working beh...

Stock Performance

View Interactive EDIT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Editas Medicine.
Current Price: $34.70
Prev Close: $35.11
Open: $35.50
Bid: $34.66
Ask: $34.73
Day's Range: $34.52 - $36.33
52wk Range: $13.12 - $41.60
Volume: 253,047
Avg Vol 1,652,376
Market Cap: $1B
P/E (ttm): -10.87
EPS (ttm): ($3.23)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Editas Medicine.
CAPS Rating 4 out of 5
131 Outperform
6 Underperform
CAPS All Stars
53 Outperform
1 Underperform

How do you think Editas Medicine will perform against the market?

You pick for Editas Medicine is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Katrine Bosley, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Editas Medicine.

The biotechnology company is a pioneer in gene editing.

  • Exchange: NASDAQ